GleamWall
中文EN

LAB STANDARD BIOTOOLS INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1162194 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-2.2%
TTM net income YoY203.8%
TTM EPS YoY203.0%
Revenue 3-yr CAGR-7.1%
Net income 3-yr CAGR—

Margins

Gross margin52.2%
Operating margin-97.5%
Net margin157.6%
FCF margin-77.8%
EBITDA margin-91.3%

Returns

ROE27.9%
ROA22.7%
ROIC (approx.)-23.4%
Asset turnover0.14x

Leverage & solvency

Liabilities / assets12.5%
Debt / equity0.00x
Current ratio9.75x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-0.48x
Accruals ratio33.6%
Payout ratio—
Capex / revenue1.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$85.33M$91.01M
Cost of revenue$42.79M$46.12M
Gross profit$42.54M$44.88M
R&D expense$25.99M$28.83M
SG&A expense$109.86M$103.06M
Operating income-$110.25M-$127.48M
Pretax income-$96.70M-$90.40M
Income tax-$37.88M$542,000
Net income-$74.90M-$138.88M
EBITDA-$100.99M-$114.97M
EPS (basic)-0.20-0.52
EPS (diluted)-0.20-0.52
Weighted avg. shares (diluted)381.62M353.25M
Balance sheet
Cash & equivalents$120.86M$168.82M
Short-term investments$66.71M$126.15M
Receivables$13.43M$14.74M
Inventory$19.98M$20.74M
Current assets$454.26M$375.88M
PP&E, net$19.27M$22.77M
Goodwill—$111.30M
Intangibles—$28.95M
Total assets$567.75M$612.35M
Current liabilities$108.31M$65.89M
Long-term debt—$299,000
Total debt—$299,000
Total liabilities$143.46M$140.62M
Shareholders' equity$424.29M$471.72M
Net debt—-$168.52M
Shares outstanding386.38M377.53M
Cash flow statement
Operating cash flow-$74.34M-$143.45M
Capital expenditure$8.30M$8.36M
Free cash flow-$82.65M-$151.81M
Investing cash flow$27.41M$363.17M
Financing cash flow$570,000-$102.62M
Depreciation & amortization$9.26M$12.52M
Stock-based compensation$29.61M$31.73M
Share buybacks$0$40.49M

Free plan shows the latest 2 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.